Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Daiichi's Pexidartinib Likely Needs REMS For Liver Safety Concerns

13 May 2019

• By Derrick Gingery

Cancer cells on scientific background.3d illustration — Daiichi Sankyo's pexidartinib showed a statistically significant improvement in overall response rate in TCGT patients compared to placebo. • Source: Shutterstock

Related Content

Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

03 Mar 2019

Daiichi's AML Drug Quizartinib Heads To ODAC With Host Of Efficacy, Safety Issues

14 May 2019

Phase III Data ENLIVEN Pexidartinib’s Prospects But Liver Tox An Issue?

06 Jun 2018

Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity

25 Oct 2016

Related Companies

Daiichi Sankyo Co., Ltd.

Additional Topics

United States Advisory Committees Drug Safety Drug Review Regulation FDA Cancer BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.